Kicking off next Wednesday, July 24th, 2024, the BIO Asia-Taiwan International Conference and Exhibition is back for its sixth year, bringing together biotech leaders from Taiwan, the US, Japan, and beyond to explore global business opportunities! 

This year's theme, Global View, Asian Touch, will feature conferences on Innovative Technologies, Investment Summits, and Regional Cooperation Forums. Plus, don't miss the Bio Asia Taiwan onsite Exhibition, One-on-one Partnering, Company Presentations, and Satellite symposia.

Among them, Company Presentations have attracted numerous high-performing teams annually. This year, the organizers are expanding our focus to include Pharmaceuticals, New Drug Development, Device & Diagnostics, Service Providers, and CDMO. Over 30 companies from around the world will participate, offering precise one-on-one partnering services for the industry.

Prominent bio companies from Taiwan, including Formosa Laboratories, Formosa Pharmaceuticals, EirGenix, Bora Group, Teclison, AnHorn Medicines, and UBI Pharma, are set to present. Regenerative medicine companies like Arce Therapeutics and ACRO Biomedical will also be featured, along with diagnostics and medical imaging companies such as EpiSonica, Pulxion Medical Technology, and ABC-KY.

The highlights of the event this year's are top international participants, including Japan's FUJIFILM, Rakuten Medical, AdipoSeeds, and ORTHOREBIRTH; the USA's Astrid Pharma Corp., Calyx / Invicro, VerImmune, and ANEUVO; and Europe's Single Use Support (SUS) and Bachem.

Save the dates: July 25-26 for their exciting exhibitions at the BIO Asia-Taiwan 2024!

 

Highlights of international participants

FUJIFILM	FUJIFILM Diosynth Biotechnologies is an industry-leading cGMP Contract Development and Manufacturing Organization (CDMO) supporting the biopharmaceutical industry in the development and production of biologics, vaccines and cell and gene therapies. Our focus is to combine technical leadership in process development and cGMP manufacturing supported by a strong team of over 4,000 employees and a reputation for excellent customer service. We are a trusted partner of many clients, from early stage biotechs to large pharma.
AdipoSeeds	AdipoSeeds are a company with transcendent technology for Cell Therapies established by Dr. Yumiko Matsubara, current visiting professor, Keio University. Our corporate mission is “Creating new Blood Supply System by making Platelets from Fat tissue” to use our main platform ASCL-PLC (Adipose-derived mesenchymal Stem Cell Line-derived Platelet-Like Cell). Currently, blood supply to patients who needs platelet transfusion is unstable due to their supply systems and aging society in many countries and ASCL-PLC can solve the problem. ASCL-PLC is Platelet-Like Cells created from donated Fat Tissues without any gene transfer or complicated biochemical processes. We are now developing some attractive modalities for cell therapies.
Single Use Support GmbH	Single Use Support is a pioneering process solution provider specializing in fluid and cold chain management of drug substances. The company focuses on the development of solutions to provide manufacturers with 100% safe and efficient handling, liquid transfer, freezing and cold chain shipping of advanced therapies and biologics in pharmaceutical production. Single Use Support is headquartered in Austria and also operates from a US subsidiary and a wide distribution network in Asia & Pacific. Approximately 200 associates globally ensure that innovation continuous and products and services simplify the life of global biopharma and advanced therapies clients.
Calyx / Invicro	Calyx / Invicro is a trusted global provider of scientific and medical expertise for imaging strategy, implementation, and analysis in clinical trials. The organizations have combined to create a new global leader in the provision of medical imaging solutions and to deliver the broadest range of preclinical – late-phase imaging services in the industry, including imaging biomarkers, core lab services, analytics, and software.   With operations in six countries, Calyx / Invicro helps global pharmaceutical, biotech, and contract research organizations achieve their development objectives in key therapeutic areas including oncology, central nervous system, and respiratory, and is meeting the growing demand for enhanced imaging and new therapies in fast-growing specialties such as radiotherapy, gastroenterology, inflammation, fibrosis, and mitochondrial imaging.
Astrid Pharma Corp	Astrid Pharma Corp have developed a novel drug delivery technology that has the potential to overcome the formidable challenge of drug resistance. Our technology, based on viral vector nanoparticle engineering , the quest of Dr Holland Cheng, Professor of virology UC Davis. By 30 years of virology and virus selection his discovery has multiple competitive advantages to all drug-delivery-systems in today drug markets, it effectively circumvents resistance mechanisms, enhancing the efficacy and reducing the side effects of existing and emerging drugs.   Astrid Pharma Corp have engineered key residues on the exterior arms of BioCapZ to chemically or genetically carry small peptides or imaging agents such as nanogoldclusters.   There are 60 protruding arms on the BioCapZ which allow for multiple application simultaneously. BioCapZ has positively charged amino acids on the interior walls, which allows for encapsulation of negatively charged cargo. The cargo can range from DNA, RNA, mRNA, shRNA, and proteins to inorganic metals like Iron Oxide.
VerImmune Inc.	VerImmune Inc is developing an innovative Virus-inspired Particle (ViP™) platform with the potential to treat multiple diseases. Their primary focus is Oncology, utilizing a unique cancer immunotherapy called Anti-tumor Immune Redirection (AIR). This method leverages the body’s existing immune memory from past infections or vaccinations to fight cancer. VerImmune's technology could revolutionize the Immuno-Oncology market, offering new treatments for patients with limited options or resistance to current therapies. Beyond Oncology, VerImmune is exploring other areas of unmet need, employing ViPs with novel properties and mechanisms to disrupt conventional treatments.

Source: https://bioasiataiwan.com/zhtw/program/detail/46